References

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Guidelines on the Management of Latent Tuberculosis Infection. Geneva: World Health Organization; 2015.

Guidelines on the Management of Latent Tuberculosis Infection.

Show details

Contents

< Prev Next >

References

1.: Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009;33:956–73. [PubMed: 19407047]
2.: Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677–86. [PubMed: 10517722]
3.: Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99:131–8. [PubMed: 4810628]
4.: Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology. 2010;15:603–22. [PubMed: 20409026]
5.: Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011.
6.: Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva: World Health Organization; 2012. [PubMed: 24404639]
7.: WHO handbook for guideline development. Geneva: World Health Organization; 2012.
8.: Use of tuberculosis interferon-gamma release assays (IGRAS) in low- and middle-income countries. Policy statement. Geneva: World Health Organization; 2011. [PubMed: 26269875]
9.: Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924. [PMC free article: PMC2335261] [PubMed: 18436948]
10.: McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, Castro KG, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis. 2005;41:1125–33. [PubMed: 16163632]
11.: Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection - a network meta-analysis. Ann Intern Med. Published online first at www.annals.org on August 2014.12. [PubMed: 25111745] [CrossRef]
12.: Comstock G. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Counterpoint. Int J Tuberc Lung Dis. 1999;3:847–50. [PubMed: 10524579]
13.: Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatric reports. 2011;3:E16. [PMC free article: PMC3133498] [PubMed: 21772953]
14.: Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics. 2002;109:765–71. [PubMed: 11986434]
15.: Attamna A, Chemtob D, Attamna S, Fraser A, Rorman E, Paul M, et al. Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax. 2009;64:271. [PubMed: 19252032]
16.: Denholm JT, Leslie DE, Jenkin GA, Darby J, Johnson PD, Graham SM, et al. Long-term follow-up of contacts exposed to multidrug-resistant tuberculosis in Victoria, Australia, 1995–2010. Int J Tuberc Lung Dis. 2012;16:1320–5. [PubMed: 22863690]
17.: Kritski AL, Marques MJ, Rabahi MF, Vieira MA, Werneck-Barroso E, Carvalho CE, et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 1996;153:331–5. [PubMed: 8542139]
18.: A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis: enhancing the safety of the TB patient. Geneva: World Health Organization; 2012.
19.: Canadian Tuberculosis Standards. 7th edition. Ontario: Public Health Agency of Canada; 2014.
20.: Latent tuberculosis infection: a guide for primary health care providers. Atlanta: Centers of Disease Control and Prevention; 2013.
21.: German Central Committee against Tuberculosis (DZK); German Respiratory Society (DGP). Recommendations for Therapy, Chemoprevention and Chemoprophylaxis of Tuberculosis in Adults and Children. Pneumologie. 2012;66:133–71. [PubMed: 22328186]
22.: Tuberculosis - Clinical diagnosis and management of tuberculosis, and measures for its prevention and control Manchester. United Kingdom: National Institute for Health and Clinical Excellence; 2011. [PubMed: 22720337]
23.: Tuberkulos Vägledning för sjukvårdspersonal. Stockholm, Sweden: Ministry of Health; 2009. [25 June 2014]. Available at: http://www.socialstyrelsen.se/smittskydd/sjukdomar/smittsammasjukdomarochsmittamnen/tuberkulos.
24.: Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365:11–20. [PMC free article: PMC3407678] [PubMed: 21732833]
25.: Swaminathan S, Menon PA, Gopalan N, Perumal V, Santhanakrishnan RK, Ramachandran R, et al. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. Plos One. 2012;7:E47400. [PMC free article: PMC3522661] [PubMed: 23251327]
26.: Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:1588–98. [PubMed: 21492926]
27.: Tortajada C, Martinez-Lacasa J, Sanchez F, Jimenez-Fuentes A, De Souza M, García J, et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis. 2005;9:276–81. [PubMed: 15786890]
28.: Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45:715–22. [PubMed: 17712755]
29.: Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–66. [PubMed: 22150035]
30.: Malotte CK, Hollingshead JR, Larro M. Incentives vs outreach workers for latent tuberculosis treatment in drug users. Am J Prev Med. 2001;20:103–7. [PubMed: 11165450]
31.: Batki SL, Gruber VA, Bradley JM, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend. 2000;66:283–93. [PubMed: 12062463]
32.: Tulsky J, Hahn J, Long H, Chambers D, Robertson M, Chesney M, et al. Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. Int J Tuberc Lung Dis. 2004;8:83–91. [PubMed: 14974750]
33.: White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Menendez E. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med. 2002;162:1044–50. [PubMed: 11996616]
34.: Hirsch-Moverman Y, Colson P, Bethel J, Franks J, El-Sadr W. Can a peer-based intervention impact adherence to the treatment of latent tuberculous infection? Int J Tuberc Lung Dis. 2013;17:1178–85. [PMC free article: PMC4477799] [PubMed: 23928167]
35.: Hovell MF, Sipan CL, Blumberg EJ, Hofstetter CR, Slymen D, Friedman L, et al. Increasing Latino adolescents' adherence to treatment for latent tuberculosis infection: a controlled trial. Am J Public Health. 2003;93:1871–7. [PMC free article: PMC1448065] [PubMed: 14600055]
36.: Kominski GF, Varon SF, Morisky DE, Malotte CK, Ebin VJ, Coly A, et al. Costs and cost-effectiveness of adolescent compliance with treatment for latent tuberculosis infection: results from a randomized trial. J Adolesc Health. 2007;40:61–8. [PubMed: 17185207]
37.: Nyamathi A, Christiani A, Nahid P, Gregerson P, Leake B. A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis. 2006;10:775–82. [PubMed: 16848340]
38.: Goldberg S, Wallace J, Jackson J, Chaulk C, Nolan C. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis. 2004;8:76–82. [PubMed: 14974749]
39.: Guidance on ethics of tuberculosis prevention, care and control. Geneva: World Health Organization; 2010.
40.: Denholm JT, McBryde ES, Brown GV. Ethical evaluation of immigration screening policy for latent tuberculosis infection. Aust N Z J Public Health. 2012;36:325–8.
41.: Kass NE. An ethics framework for public health. Am J Public Health. 2001;91:1776–82. [PMC free article: PMC1446875] [PubMed: 11684600]

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution–should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

Bookshelf ID: NBK293814

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Guidelines on the Management of Latent Tuberculosis Infection. Geneva: World Health Organization; 2015. References.
PDF version of this title (2.6M)